BR112021023209A2 - Terapia com vacina anti-abeta - Google Patents
Terapia com vacina anti-abetaInfo
- Publication number
- BR112021023209A2 BR112021023209A2 BR112021023209A BR112021023209A BR112021023209A2 BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2 BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2
- Authority
- BR
- Brazil
- Prior art keywords
- administered
- vaccine therapy
- mpla
- amyloid
- amount
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023209A2 true BR112021023209A2 (pt) | 2022-01-18 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023209A BR112021023209A2 (pt) | 2019-05-21 | 2020-05-20 | Terapia com vacina anti-abeta |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (enExample) |
| EP (1) | EP3972633A1 (enExample) |
| JP (1) | JP7701734B2 (enExample) |
| KR (1) | KR20220010552A (enExample) |
| CN (1) | CN113853214A (enExample) |
| AU (1) | AU2020277682A1 (enExample) |
| BR (1) | BR112021023209A2 (enExample) |
| CA (1) | CA3138145A1 (enExample) |
| CL (1) | CL2021003051A1 (enExample) |
| IL (1) | IL288252A (enExample) |
| MX (1) | MX2021014102A (enExample) |
| MY (1) | MY210394A (enExample) |
| SG (1) | SG11202112329RA (enExample) |
| TW (1) | TW202110425A (enExample) |
| WO (1) | WO2020234405A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
| KR20250137159A (ko) * | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| AU2019253193B2 (en) | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020234405A1 (en) | 2020-11-26 |
| CA3138145A1 (en) | 2020-11-26 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (en) | 2022-03-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| JP2022533422A (ja) | 2022-07-22 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| SG11202112329RA (en) | 2021-12-30 |
| MX2021014102A (es) | 2022-02-11 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| MY210394A (en) | 2025-09-18 |
| IL288252A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023209A2 (pt) | Terapia com vacina anti-abeta | |
| Luo et al. | The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| BRPI0920791B8 (pt) | Uso de peptídeo na preparação de medicamento para tratar câncer e kit | |
| BR112020016454A8 (pt) | Tratamento utilizando rna que codifica citocina | |
| CA2943334A1 (en) | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof | |
| ES2262460T1 (es) | Prevencion y tratamiento de enfermedad amiloidogenica. | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| BR0108924A (pt) | Composição umonogênica adaptada para administração a um hospedeiro humano para o tratamento ou prevenção da aterosclerose, vacina, e, método de tratamento ou profilaxia da aterosclerose | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| TW200722101A (en) | Novel composition | |
| BR112021021213A2 (pt) | Administração heteróloga de vacinas de tau | |
| JP2015500827A5 (enExample) | ||
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| CN103533953A (zh) | 针对肺炎链球菌的疫苗 | |
| JP2021521149A5 (enExample) | ||
| BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
| JP2015529677A5 (enExample) | ||
| BRPI0417225A (pt) | métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos | |
| BR112021022087A2 (pt) | Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus | |
| US20230285531A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| ES2547855T3 (es) | Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria | |
| CO2025016879A2 (es) | Composiciones para el uso en el tratamiento del acné |